- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Pie Medical Imaging Launches AI-Powered Echocardiography Platform
CAAS Qardia 2.0, an updated version of the CAAS Qardia echocardiography software platform, reportedly incorporates artificial intelligence (AI)-enabled workflows, and provides enhanced imaging and analysis of key cardiac measures.
Combining off-cart echocardiography analysis with artificial intelligence (AI) capabilities, Pie Medical Imaging has launched the FDA-cleared CAAS Qardia 2.0 platform.
An update to the company’s CAAS Qardia echocardiography software, the CAAS Qardia 2.0 software offers robust visualization of stress-echo imaging and diastolic function, and reportedly excels at analysis of myocardial strain and other cardiac assessments, according to Pie Medical Imaging.
The company notes that quality control indices with the CAAS Qardia 2.0 platform enable clinicians to counteract potential foreshortening of cardiac imaging that may impact measurements such as myocardial strain. Leveraging AI-powered workflows, the CAAS Qardia 2.0 software generates automated reporting of key parameters.
Pie Medical imaging adds that the CAAS Qardia software can be server-based with access from any PC within a hospital network or be deployed in a stand-alone setup.
(Editor's note: For a related article, see "FDA Clears AI-Powered Echocardiography Platform for Detecting Heart Failure with Preserved Ejection Fraction.")
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
